Hepatitis C: Optimizing Treatment

Interferon Therapies in Difficult-to-Treat Patients and Hepatitis C Disease Progression

Rush-Presbyterian-St. Luke’s Medical Center is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. Rush-Presbyterian-St. Luke’s Medical Center designates this continuing medical education activity for 2.0 hours in Category 1 of the Physicians Recognition Award of the American Medical Association. Rush-Presbyterian-St. Luke’s Medical Center takes responsibility for the content, quality, and scientific integrity of this CME activity.


Target Audience
The target audience for this program includes hepatologists, gastroenterologists and other physicians with an interest or specialty in treatment of Hepatitis C.

Educational Objectives

At the conclusion of the course, the participant should be better able to:
Identify options and innovations in the treatment of hepatitis C, especially in difficult-to-treat patients.
Review the role of prognostic indicators as predictors of success in treatment and management of hepatitis C, especially in difficult-to-treat patients.
Discuss optimizing interferon treatments for hepatitis C with respect to patient types, especially difficult-to-treat patients.
Describe current trends in the optimization of interferon therapies, including aggressive interferon regimens, combination therapies and the latest information on pegylated interferons.
Discuss the role of present and future interferon therapies in hepatitis C disease progression, including cirrhosis, hepatocellular carcinoma and liver transplant.

Faculty Disclosure

It is the policy of the Rush-Presbyterian-St. Luke’s Medical Center Office of Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all its individually sponsored educational programs. All faculty participating in any Rush-Presbyterian-St. Luke’s Medical Center sponsored programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It remains for the audience to determine whether the speaker’s outside interests may reflect a possible bias in either the exposition or the conclusions presented.

Donald Jensen, MD: Research Support, Amgen, Glaxo-Wellcome, F. Hoffmann-La Roche, Ltd., Schering-Plough; Consultant, Amgen, F. Hoffmann-La Roche, Ltd.; Speakers’ Bureau, Amgen, F. Hoffmann-La Roche, Ltd., Schering-Plough.

Russell H. Wiesner, MD: Research Support, F. Hoffmann-La Roche, Ltd.
Michael Fried, MD: Research Support, F. Hoffmann-La Roche, Ltd., Gilead Pharmaceuticals, Schering-Plough; Consultant, F. Hoffmann-La Roche, Ltd.; Speakers’ Bureau, F. Hoffmann-La Roche, Ltd., Schering-Plough.

Jorge Rakela, MD: Research Support, Schering-Plough, F. Hoffmann-La Roche, Ltd., Glaxo-Wellcome.

Ferruccio Bonino, MD: Research Support, Novartis, Ortho Diagnostics, Bristol Myers Squibb, Gilead Pharmaceuticals, F. Hoffmannn-La Roche, Ltd., Schering-Plough; Speakers’ Bureau, F. Hoffmann-La Roche, Ltd., Glaxo-Wellcome.

Donald M. Jensen, MD

Chair and CME Advisor
Rush-Presbyterian-St. Luke’s Medical Center
Chicago, Illinois

Sharing is caring!

Leave a Comment